Recombinant MDV Vector for Stable ILTV and IBDV Antigen Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing multivalent recombinant Marek's Disease virus (rMDVnp) vectors struggle to stably express antigens from multiple poultry viruses, leading to unpredictable suitability and inefficiencies in vaccination, as they often result in overgrowth and inadequate immune responses.
Innovation Solution
A novel recombinant non-pathogenic Marek's Disease virus (rMDVnp) vector, such as rHVT or rMDV2, is designed to express foreign genes from Infectious Laryngotracheitis Virus (ILTV) and Infectious Bursal Disease Virus (IBDV) by inserting heterologous nucleic acids into nonessential sites of the rMDVnp genome, using specific promoters and transcription terminators to ensure stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple recombinant monovalent rMDVnp constructs are used in alternative multivalent vaccines, then protection against multiple viral pathogens is attempted, but one construct overgrows the other constructs preventing significant immune response
Solution Approach 1:
The patent combines multiple viral antigens (ILTV gD, ILTV gI, and IBDV VP2) into a single recombinant rMDVnp construct rather than using separate monovalent constructs. This merging approach eliminates the overgrowth problem between competing viral constructs while maintaining protection against multiple pathogens through a unified vaccine vector.
Solution Approach 2:
The rMDVnp vector is designed as a universal platform capable of expressing multiple foreign genes from different viral pathogens simultaneously. The single construct serves multiple protective functions against ILTV and IBDV through coordinated expression of heterologous antigens, demonstrating multi-functionality in a unified vaccine system.
2Adaptability or versatility
If multiple separate injections are given to chicks for multivalent vaccination, then protection against multiple pathogens is achieved, but discomfort and stress on the chick increases
Solution Approach 1:
The patent merges multiple vaccine antigens into a single recombinant rMDVnp construct that can be administered through one injection. This consolidation reduces the number of vaccination procedures from multiple separate injections to a single administration, thereby decreasing chick stress and simplifying the vaccination process while maintaining multivalent protection.
3Adaptability or versatility
If multiple separate injections are used for multivalent vaccination, then comprehensive pathogen coverage is achieved, but labor and material costs increase
Solution Approach 1:
The patent combines multiple pathogen antigens into a single recombinant vaccine construct, reducing the number of vaccination operations required. This merging approach decreases labor requirements and material consumption associated with multiple separate injections, thereby improving vaccination efficiency and reducing costs while maintaining comprehensive pathogen coverage.
Data Source
AI summary
The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.